JP5816100B2 - 多能性細胞の分化 - Google Patents

多能性細胞の分化 Download PDF

Info

Publication number
JP5816100B2
JP5816100B2 JP2011552223A JP2011552223A JP5816100B2 JP 5816100 B2 JP5816100 B2 JP 5816100B2 JP 2011552223 A JP2011552223 A JP 2011552223A JP 2011552223 A JP2011552223 A JP 2011552223A JP 5816100 B2 JP5816100 B2 JP 5816100B2
Authority
JP
Japan
Prior art keywords
cells
differentiation
medium
cell
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011552223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519005A5 (cg-RX-API-DMAC7.html
JP2012519005A (ja
Inventor
ディーピカ ラジェシュ，
ディーピカ ラジェシュ，
レイチェル ルイス，
レイチェル ルイス，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド, セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2012519005A publication Critical patent/JP2012519005A/ja
Publication of JP2012519005A5 publication Critical patent/JP2012519005A5/ja
Application granted granted Critical
Publication of JP5816100B2 publication Critical patent/JP5816100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011552223A 2009-02-27 2010-03-01 多能性細胞の分化 Active JP5816100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15630409P 2009-02-27 2009-02-27
US61/156,304 2009-02-27
PCT/US2010/025776 WO2010099539A1 (en) 2009-02-27 2010-03-01 Differentiation of pluripotent cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015158092A Division JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Publications (3)

Publication Number Publication Date
JP2012519005A JP2012519005A (ja) 2012-08-23
JP2012519005A5 JP2012519005A5 (cg-RX-API-DMAC7.html) 2013-04-18
JP5816100B2 true JP5816100B2 (ja) 2015-11-18

Family

ID=42097524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011552223A Active JP5816100B2 (ja) 2009-02-27 2010-03-01 多能性細胞の分化
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Country Status (9)

Country Link
US (2) US8372642B2 (cg-RX-API-DMAC7.html)
EP (1) EP2401364B1 (cg-RX-API-DMAC7.html)
JP (2) JP5816100B2 (cg-RX-API-DMAC7.html)
KR (1) KR101720961B1 (cg-RX-API-DMAC7.html)
CN (1) CN102388130B (cg-RX-API-DMAC7.html)
AU (1) AU2010217739B2 (cg-RX-API-DMAC7.html)
CA (1) CA2753679C (cg-RX-API-DMAC7.html)
IL (1) IL214818A (cg-RX-API-DMAC7.html)
WO (1) WO2010099539A1 (cg-RX-API-DMAC7.html)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013331A2 (en) 2006-04-14 2009-01-14 Advanced Cell Technology, Inc. Hemangio-colony forming cells
JP5804280B2 (ja) * 2009-09-08 2015-11-04 国立大学法人京都大学 多能性幹細胞からの肥満細胞の製造方法
EP3633025B1 (en) 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US8703487B2 (en) * 2009-12-01 2014-04-22 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
AU2010326027A1 (en) * 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
WO2011106681A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University SMOOTH MUSCLE-LIKE CELLS (SMLCs) DERIVED FROM HUMAN PLURIPOTENT STEM CELLS
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
EP2615165B1 (en) 2010-09-10 2016-08-03 The University of Tokyo Culture method related to differentiation of pluripotent stem cells into blood cells
WO2012103098A2 (en) * 2011-01-24 2012-08-02 Immunepath, Inc. Compositions and methods for treating hematological cytopenias
JP6148429B2 (ja) * 2011-01-31 2017-06-14 協和発酵バイオ株式会社 ヒト多能性幹細胞の培養方法
CA2826386C (en) * 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
CN102161980B (zh) * 2011-02-12 2013-07-31 浙江大学 用人间充质干细胞为滋养层培养诱导多能干细胞的方法
US9499789B2 (en) 2011-02-23 2016-11-22 Kyoto University Method for producing dendritic cells from pluripotent stem cells
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
GB201103600D0 (en) 2011-03-01 2011-04-13 Isis Innovation Dendritic cells
JP6185907B2 (ja) * 2011-03-30 2017-08-23 セルラー ダイナミクス インターナショナル， インコーポレイテッド 神経分化のための多能性幹細胞の予備刺激
JP6124880B2 (ja) * 2011-06-09 2017-05-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多能性幹細胞の血管床細胞への分化のための方法
EP2761065B1 (en) * 2011-09-29 2017-12-06 Cellsnap, LLC Compositions and methods for toxigenicity testing
RU2014117642A (ru) * 2011-10-03 2015-11-10 Ниссан Кемикал Индастриз, Лтд. Способ получения мегакариоцитов и/или тромбоцитов из плюрипотентных стволовых клеток
US9834754B2 (en) * 2011-11-21 2017-12-05 University Health Network Populations of hematopoietic progenitors and methods of enriching stem cells therefor
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
BR112014013152B1 (pt) 2011-12-01 2021-08-31 New York Stem Cell Foundation, Inc Sistema automatizado para geração de células-tronco pluripotentes induzidas (ipscs)
WO2013130820A1 (en) * 2012-02-29 2013-09-06 The Johns Hopkins University Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
US10286014B2 (en) * 2012-09-28 2019-05-14 Foundation For Biomedical Research And Innovation At Kobe Method for in vitro proliferation of cell population containing cells suitable for treatment of ischemic disease
HK1210190A1 (en) 2012-11-21 2016-04-15 Merz Pharma Gmbh & Co. Kgaa. Means and methods for determination of botulinum neurotoxin biological activity
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
PL2970912T3 (pl) 2013-03-13 2019-08-30 Wisconsin Alumni Research Foundation Sposoby i materiały do hematopoetyczno-śródbłonkowego różnicowania ludzkich pluripotentnych komórek macierzystych w zdefiniowanych warunkach
US9994825B2 (en) 2013-03-15 2018-06-12 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
EP2970913B1 (en) * 2013-03-15 2018-08-22 LongBoat Explorers AB Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
AU2014232381A1 (en) * 2013-03-15 2015-10-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9506037B2 (en) 2013-03-15 2016-11-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
US20160146788A1 (en) * 2013-05-23 2016-05-26 Kyoto University Method for screening drugs for treating/preventing myelodysplastic syndrome, etc.
WO2014200340A1 (en) * 2013-06-10 2014-12-18 Academisch Ziekenhuis Leiden Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures
PL3014267T3 (pl) 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
WO2015050963A1 (en) * 2013-10-01 2015-04-09 Manfred Boehm Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings
US11352606B2 (en) * 2014-02-10 2022-06-07 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
MX377115B (es) 2014-02-19 2025-03-07 Merz Pharma Gmbh & Co Kgaa Gangliosidos para estandarizacion y aumento de la sensibilidad de las celulas a las neurotoxinas botulinicas en sistemas de prueba in vitro.
AU2015249371B2 (en) 2014-04-24 2020-04-30 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
MA40552A (fr) 2014-08-04 2021-05-19 Nuevolution As Derives de pyrimidine eventuellement condensee substituee par un heterocycle utiles dans le traitement de maladies inflammatoires, metaboliques, oncologiques et auto-immunes
EP3233911B1 (en) 2014-12-19 2020-10-14 Merz Pharma GmbH & Co. KGaA Means and methods for the determination of the biological activity of bont/e in cells
JP6774952B2 (ja) * 2015-01-16 2020-10-28 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 多能性幹細胞のマクロファージへの分化
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
JP6800859B2 (ja) * 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
US11680244B2 (en) 2015-05-20 2023-06-20 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
WO2016203477A1 (en) * 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
ES2971677T3 (es) * 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
CN108350429B (zh) 2015-10-20 2022-02-25 富士胶片细胞动力公司 用于将多能干细胞定向分化为免疫细胞的方法
IL258899B2 (en) 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
EP3371314B1 (en) 2015-11-04 2023-07-05 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250033315A (ko) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 조혈 세포 분화를 유도하기 위한 방법 및 조성물
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
WO2017115865A1 (ja) * 2015-12-29 2017-07-06 株式会社クラレ 幹細胞の凝集塊の集団の調製方法
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
JP7367951B2 (ja) 2016-05-18 2023-10-24 慶應義塾 オルガノイド培養用細胞培養培地
WO2018021566A1 (ja) * 2016-07-29 2018-02-01 ダイキン工業株式会社 分化細胞の製造方法、及びその製造方法のために使用する培養バッグ
WO2018043714A1 (ja) * 2016-09-02 2018-03-08 塩野義製薬株式会社 多能性幹細胞からミクログリアを得る方法
US11525119B2 (en) 2016-09-06 2022-12-13 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
BR112019006910A2 (pt) * 2016-10-05 2019-07-02 Fujifilm Cellular Dynamics Inc métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
CN106754684A (zh) * 2017-01-05 2017-05-31 厚朴生物科技（苏州）有限公司 一种睾丸间质干细胞分离培养分化方法
EP3587560A4 (en) 2017-01-27 2020-12-16 Kaneka Corporation Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
EP3576756A4 (en) * 2017-02-03 2020-12-16 Cornell University STABLE THREE-DIMENSIONAL BLOOD VESSELS AND THEIR FORMATION PROCESSES
AU2018240416B2 (en) * 2017-03-21 2024-07-11 Centre National De La Recherche Scientifique Methods of improving hematopoietic grafts
KR102668891B1 (ko) * 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 항원-특이적 면역 이펙터 세포
EP3399027A1 (en) 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
CN107083367B (zh) * 2017-07-03 2020-07-14 广州润虹医药科技股份有限公司 培养基及其用途与由尿液细胞制备间充质干细胞的方法
WO2019117444A1 (ko) * 2017-12-11 2019-06-20 대한민국(관리부서 질병관리본부장) 전분화능 줄기세포를 이용한 면역세포 분화
WO2019126146A1 (en) 2017-12-19 2019-06-27 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
CN108048390B (zh) * 2017-12-21 2021-04-27 清华大学 一种制备血管内皮细胞的方法及其专用试剂盒
CN108588024B (zh) * 2017-12-29 2020-04-21 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 诱导多能干细胞分化成造血干细胞的培养基及方法
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
MY199514A (en) 2018-02-01 2023-11-02 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
IL281413B2 (en) 2018-09-19 2024-09-01 Fujifilm Cellular Dynamics Inc Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
WO2020086889A1 (en) * 2018-10-24 2020-04-30 Hebecell Corporation Methods and systems for manufacturing hematopoietic lineage cells
KR102111441B1 (ko) * 2018-11-12 2020-05-15 대한민국 전분화능 줄기세포 유래 대식세포를 기반으로 하는 감염질환 치료용 약물 스크리닝 방법
SG11202106642YA (en) 2018-12-20 2021-07-29 Sumitomo Chemical Co Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method
JP7634938B2 (ja) * 2019-02-21 2025-02-25 ピービーエス バイオテック インコーポレイテッド バイオリアクターにおける治療細胞の膨張および分化のためのシステムおよび方法
CN111206017B (zh) * 2019-04-30 2022-02-18 浙江大学 一种干细胞无血清培养基及其应用
WO2020252477A1 (en) * 2019-06-14 2020-12-17 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
CA3154422A1 (en) 2019-10-18 2021-04-22 Jan TALTS Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
JP7479466B2 (ja) * 2019-11-13 2024-05-08 カリス バイオ インコーポレイテッド 血管内皮細胞純粋分離方法、血管内皮細胞特性維持培地及びそれを含む培養方法
CN110938584B (zh) * 2019-11-25 2021-12-03 广州赛莱拉干细胞科技股份有限公司 一种人胚胎干细胞向内皮细胞诱导分化的方法
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
AU2020408107A1 (en) 2019-12-20 2022-04-14 Nuevolution A/S Compounds active towards nuclear receptors
WO2021173458A1 (en) * 2020-02-28 2021-09-02 Purdue Research Foundation Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
US12220445B2 (en) 2020-03-09 2025-02-11 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
CN111440760B (zh) * 2020-03-09 2022-09-23 浙江大学 一种人多能干细胞高效分化得到内皮祖细胞的方法
US11547726B2 (en) 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CN115885038A (zh) 2020-06-17 2023-03-31 国立大学法人京都大学 表达嵌合抗原受体的免疫活性细胞
CA3174380A1 (en) * 2020-07-27 2022-02-03 Stemcell Technologies Canada Inc. Systems and methods for differentiating hematopoietic cells
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022255166A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
AU2022253891A1 (en) 2021-04-07 2023-08-24 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
IL307358A (en) 2021-04-07 2023-11-01 Century Therapeutics Inc Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
KR20240006059A (ko) 2021-05-05 2024-01-12 후지필름 셀룰러 다이내믹스, 인코포레이티드 Ipsc-유래된 미세아교세포에 대한 방법 및 조성물
CN118234849A (zh) 2021-09-10 2024-06-21 富士胶片细胞动力公司 诱导多能干细胞衍生细胞的组合物及其使用方法
EP4402164A4 (en) * 2021-09-13 2025-07-02 Amprion Inc INERT MATRICES FOR QUALITATIVE AND SEMI-QUANTITATIVE SEED AMPLIFICATION ASSAYS
CA3238399A1 (en) 2021-12-15 2023-06-22 Torben LUND-HANSEN Scfv and antibodies with reduced multimerisation
US20250064934A1 (en) 2021-12-29 2025-02-27 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
EP4519319A1 (en) 2022-05-04 2025-03-12 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CA3257424A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically modified cells expressing variants of CD16 and NKG2D and their uses
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
EP4615876A2 (en) 2022-11-10 2025-09-17 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
AU2024223390A1 (en) * 2023-02-16 2025-08-28 Syntax Bio, Inc. Systems for cell programming towards hematopoietic lineage and methods thereof
CN116426472A (zh) * 2023-06-08 2023-07-14 呈诺再生医学科技(北京)有限公司 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
CA2259012C (en) 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
ATE374026T1 (de) 1999-03-25 2007-10-15 Mitsubishi Pharma Corp Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
EP1491093B1 (en) * 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
IL162130A0 (en) * 2001-12-07 2005-11-20 Robarts Res Inst Hematopoietic cells from human embryonic stem cells
EP1458854B1 (en) * 2001-12-21 2010-04-14 Mount Sinai Hospital Cellular compositions and methods of making and using them
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
WO2003089457A2 (en) 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c ϝ for pain management
US7723106B2 (en) * 2004-07-29 2010-05-25 Food Industry Research & Development Institute Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same
CN1938023A (zh) 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
GB2432846B (en) * 2004-09-08 2009-12-30 Wisconsin Alumni Res Found Medium and culture of embryonic stem cells
WO2006050330A2 (en) 2004-11-01 2006-05-11 Wisconsin Alumni Research Foundation Platelets from stem cells
US20070077654A1 (en) 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
EP1860180A4 (en) 2005-02-23 2009-03-11 Found Biomedical Res & Innov METHOD FOR THE AMPLIFICATION OF AN ENDOTHEL PREPARATION CELL IN VITRO
JP2009517085A (ja) * 2005-11-28 2009-04-30 チョンウェ ファーマ コーポレイション 培養における細胞の無血清増殖
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
JP5067949B2 (ja) * 2006-11-09 2012-11-07 独立行政法人国立国際医療研究センター 霊長類動物胚性幹細胞の培養及び継代方法、並びにその分化誘導方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
SG10201610881UA (en) * 2008-03-27 2017-03-30 Asterias Biotherapeutics Inc Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
WO2009135206A1 (en) * 2008-05-02 2009-11-05 Stem Cell Products, Inc. Method for production of mast cells from stem cells
WO2010035136A2 (en) * 2008-09-25 2010-04-01 Uti Limited Partnership Expansion of embryonic stem cells

Also Published As

Publication number Publication date
US20130210141A1 (en) 2013-08-15
CA2753679C (en) 2021-03-02
CN102388130B (zh) 2014-08-27
US10100282B2 (en) 2018-10-16
EP2401364B1 (en) 2015-04-22
IL214818A0 (en) 2011-11-30
CN102388130A (zh) 2012-03-21
CA2753679A1 (en) 2010-09-02
JP2012519005A (ja) 2012-08-23
KR20110122858A (ko) 2011-11-11
US20100279403A1 (en) 2010-11-04
WO2010099539A1 (en) 2010-09-02
AU2010217739B2 (en) 2015-09-03
AU2010217739A1 (en) 2011-09-08
KR101720961B1 (ko) 2017-03-29
US8372642B2 (en) 2013-02-12
JP2015192681A (ja) 2015-11-05
EP2401364A1 (en) 2012-01-04
IL214818A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
JP5816100B2 (ja) 多能性細胞の分化
JP2012519005A5 (cg-RX-API-DMAC7.html)
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
JP6189581B2 (ja) 幹細胞の分化のための方法および組成物
US20200157503A1 (en) Hemangio colony forming cells and non-engrafting hemangio cells
CN117264888A (zh) 一种制备造血干细胞和祖细胞的方法
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150925

R150 Certificate of patent or registration of utility model

Ref document number: 5816100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250